Vera CEO sells 18,500 shares after exercising options
Rhea-AI Filing Summary
Vera Therapeutics, Inc. (VERA) reports that President and CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock on September 15, 2026 at an exercise price of $2.8968 per share, then sold 18,500 shares at $37.00 per share under a Rule 10b5-1 trading plan. Following the option exercise, he held 488,801 options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 18,500 shares ($631K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Fordyce Marshall
Role
PRESIDENT AND CEO
Sold
18,500 shs ($685K)
Approx. gross sale proceeds
$685K
Approx. exercise cost
$54K
Approx. pre-tax spread
$631K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2 | 18,500 | $0.00 | $0.00 |
| Exercise | Class A Common Stock | 18,500 | $2.8968 | $54K |
| Sale | Class A Common Stock F1 | 18,500 | $37.00 | $685K |
Holdings After Transaction:
Stock Option (Right to Buy) — 488,801 contracts (Direct);
Class A Common Stock — 235,244 shares (Direct)
Footnotes (2)
- F1. The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F2. 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.
Key Figures
Shares exercised: 18,500 shares
Exercise price: $2.8968 per share
Shares sold: 18,500 shares
+4 more
7 metrics
Shares exercised
18,500 shares
Stock options exercised into Class A Common Stock on September 15, 2026
Exercise price
$2.8968 per share
Exercise price of Stock Option (Right to Buy) into Class A Common Stock
Shares sold
18,500 shares
Class A Common Stock sold on September 15, 2026
Sale price
$37.00 per share
Price for the sale of Class A Common Stock on September 15, 2026
Options held after transaction
488,801 options
Directly held Stock Option (Right to Buy) position after the exercise
Option expiration date
December 15, 2030
Expiration date of the exercised stock option series
Rule 10b5-1 plan adoption date
January 9, 2026
Adoption date of written trading plan covering the reported sales
Key Terms
Rule 10b5-1(c), Stock Option (Right to Buy), Class A Common Stock, derivative security
4 terms
Rule 10b5-1(c) regulatory
"plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
Stock Option (Right to Buy) financial
"security titled Stock Option (Right to Buy) for Class A Common Stock"
Class A Common Stock financial
"underlying security title listed as Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
derivative security financial
"described as an exercise or conversion of a derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did VERA’s CEO report on this Form 4?
Marshall Fordyce reported exercising options for 18,500 shares of Class A Common Stock at an exercise price of $2.8968 per share on September 15, 2026, and selling 18,500 shares of Class A Common Stock at $37.00 per share the same day.
Were the VERA stock sales by the CEO made under a Rule 10b5-1 plan?
Yes. The filing states the sales were made pursuant to a written plan adopted on January 9, 2026 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.
How many options does the VERA CEO hold after these transactions?
After exercising 18,500 options, Marshall Fordyce directly held 488,801 stock options, each representing the right to buy one share of VERA Class A Common Stock, with the reported option series expiring on December 15, 2030.
What prices were involved in the VERA CEO’s Form 4 transactions?
The options were exercised at an exercise price of $2.8968 per share, and the resulting 18,500 shares of Class A Common Stock were sold at $37.00 per share on September 15, 2026.
What is the vesting schedule of the VERA stock options exercised by the CEO?
For the option exercised, the filing notes that 1/4 of the shares vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter, indicating a standard multi-year vesting schedule.
What type of securities are involved in the VERA CEO’s Form 4 filing?
The filing covers both a derivative security, Stock Option (Right to Buy) VERA Class A Common Stock, and the underlying Class A Common Stock acquired through exercise and then sold.
AI-generated analysis. How Rhea-AI works. Not financial advice.
